JP2019506403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506403A5 JP2019506403A5 JP2018538596A JP2018538596A JP2019506403A5 JP 2019506403 A5 JP2019506403 A5 JP 2019506403A5 JP 2018538596 A JP2018538596 A JP 2018538596A JP 2018538596 A JP2018538596 A JP 2018538596A JP 2019506403 A5 JP2019506403 A5 JP 2019506403A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662286616P | 2016-01-25 | 2016-01-25 | |
| US62/286,616 | 2016-01-25 | ||
| PCT/IB2017/050244 WO2017130076A1 (en) | 2016-01-25 | 2017-01-17 | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506403A JP2019506403A (ja) | 2019-03-07 |
| JP2019506403A5 true JP2019506403A5 (enExample) | 2019-10-24 |
| JP6783312B2 JP6783312B2 (ja) | 2020-11-11 |
Family
ID=57956335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538596A Expired - Fee Related JP6783312B2 (ja) | 2016-01-25 | 2017-01-17 | がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190031765A1 (enExample) |
| EP (1) | EP3408294A1 (enExample) |
| JP (1) | JP6783312B2 (enExample) |
| KR (2) | KR20210013777A (enExample) |
| CN (1) | CN108473587A (enExample) |
| AU (2) | AU2017211540B2 (enExample) |
| BR (1) | BR112018014016A2 (enExample) |
| CA (1) | CA2955184A1 (enExample) |
| HK (1) | HK1259253A1 (enExample) |
| MX (1) | MX2018008995A (enExample) |
| RU (1) | RU2748949C2 (enExample) |
| WO (1) | WO2017130076A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| CN110536703B (zh) | 2017-04-20 | 2024-07-12 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
| UA127900C2 (uk) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
| EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019178852A1 (zh) * | 2018-03-23 | 2019-09-26 | 苏州丁孚靶点生物技术有限公司 | Ox40抗原多肽及其用途 |
| CN110357961B (zh) * | 2018-04-10 | 2022-08-23 | 无锡智康弘义生物科技有限公司 | 抗人4-1bb单克隆抗体及其制备方法和用途 |
| EP3773720A4 (en) | 2018-04-10 | 2022-01-05 | Wuxi Biologics (Shanghai) Co. Ltd. | MONOCLONAL ANTIBODIES AGAINST HUMAN 4-1BB, METHOD OF MANUFACTURING AND USING THEREOF |
| SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
| AU2019312200B2 (en) | 2018-07-23 | 2024-11-14 | Heidelberg Pharma Research Gmbh | Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| JP2022533833A (ja) * | 2019-05-24 | 2022-07-26 | ファイザー・インク | Ｃｄｋ阻害剤を使用した組合せ療法 |
| WO2021059136A1 (en) | 2019-09-25 | 2021-04-01 | Pfizer Inc. | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| CA3161733A1 (en) | 2020-01-07 | 2021-05-15 | Everett Stone | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| WO2021155113A1 (en) | 2020-01-29 | 2021-08-05 | Board Of Regents, The University Of Texas System | Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions |
| US20230069749A1 (en) | 2020-01-29 | 2023-03-02 | Board Of Regents, The University Of Texas System | Use of poziotinib for the treatment of cancers with nrg1 fusions |
| CA3180665A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| US20230242658A1 (en) * | 2020-06-30 | 2023-08-03 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1bb-binding protein and use thereof |
| CN114515335A (zh) * | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在治疗肿瘤或癌症中的应用 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| US11964978B2 (en) | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
| US20240182593A1 (en) * | 2021-05-27 | 2024-06-06 | Yuhan Corporation | Ox40 agonist and use thereof |
| CN118684772A (zh) * | 2021-09-09 | 2024-09-24 | 广东东阳光药业股份有限公司 | 抗4-1bb的激动型抗体及其应用 |
| WO2023056361A1 (en) | 2021-09-29 | 2023-04-06 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2873999A (en) | 1998-02-24 | 1999-09-06 | Sisters Of Providence In Oregon | Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| CA2588157A1 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| EP1896030A1 (en) | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| KR101577843B1 (ko) * | 2007-12-14 | 2015-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ｏｘ４０ 수용체에 대한 결합 분자 |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| MX2013015365A (es) | 2011-06-30 | 2014-02-11 | Michelin & Cie | Metodos y aparatos para instalacion de un anillo de rodadura en una carcasa de neumatico. |
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| MX2016015181A (es) * | 2014-05-21 | 2017-05-25 | Pfizer | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. |
| RU2766890C2 (ru) * | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
-
2017
- 2017-01-17 BR BR112018014016A patent/BR112018014016A2/pt not_active IP Right Cessation
- 2017-01-17 RU RU2018127164A patent/RU2748949C2/ru active
- 2017-01-17 US US16/069,712 patent/US20190031765A1/en not_active Abandoned
- 2017-01-17 EP EP17702687.9A patent/EP3408294A1/en not_active Withdrawn
- 2017-01-17 KR KR1020217002980A patent/KR20210013777A/ko not_active Ceased
- 2017-01-17 CN CN201780007730.6A patent/CN108473587A/zh active Pending
- 2017-01-17 AU AU2017211540A patent/AU2017211540B2/en not_active Ceased
- 2017-01-17 MX MX2018008995A patent/MX2018008995A/es unknown
- 2017-01-17 CA CA2955184A patent/CA2955184A1/en active Pending
- 2017-01-17 KR KR1020187024267A patent/KR20180103150A/ko not_active Ceased
- 2017-01-17 WO PCT/IB2017/050244 patent/WO2017130076A1/en not_active Ceased
- 2017-01-17 HK HK19101614.3A patent/HK1259253A1/zh unknown
- 2017-01-17 JP JP2018538596A patent/JP6783312B2/ja not_active Expired - Fee Related
-
2020
- 2020-07-27 AU AU2020210145A patent/AU2020210145A1/en not_active Abandoned